Press Releases

06-23 Saniona: Our take on the SAN2668 R&D day AQ
06-11 Three shots on goal: Saniona prepares to enter the clinic AQ
06-04 Saniona to Host Virtual R&D Day Focusing on SAN2668 for Severe Pediatric Epilepsies AQ
05-28 Saniona (Q1 Review): Setting up for the long run AQ
05-27 Bulletin from the Saniona AB annual shareholders’ meeting on May 27, 2026 AQ
05-26 SANA : Interim Report Q1 2026 PU
05-26 Saniona publishes its interim report for the first quarter of 2026 AQ
05-20 Invitation to Saniona Q1 investor call on 26 May 2026 AQ
04-30 Saniona publishes its Annual Report for 2025 AQ
04-27 SANA : The board's statement pursuant to Chapter 19, Section 22 of the Swedish companies Act PU
04-24 SANA : Notice of annual shareholders' meeting 2026 PU
04-24 SANA : Proposal for resolution on LTI 2026 PU
04-24 SANA : Notice of Saniona AB annual shareholders' meeting PU
04-24 Notice of Saniona AB annual shareholders’ meeting AQ
03-12 Saniona enters clinical execution phase following transformational year AQ
03-12 Meet Saniona at several conferences during the spring AQ
03-03 Saniona (Q4 review): Moving forward nicely AQ
02-26 Saniona publishes its year-end report for 2025 AQ
02-20 Invitation to Saniona Q4 & year-end investor call on 26 February 2026 AQ
12-17 Saniona Bolsters Leadership Team to Accelerate Development of Key CNS Programs AQ
12-01 Saniona comments on major advancements during third quarter AQ
11-28 Saniona (Q3 Review) - Gearing up for clinical development AQ
11-27 Saniona publishes its interim report for the third quarter of 2025 AQ
11-20 Invitation to Saniona Q3 investor call on 27 November 2025 AQ
11-06 Saniona AB’s Nomination Committee for the Annual General Meeting 2026 AQ
No results match your criteria